{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:04:42Z","timestamp":1779087882188,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90472-8","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T13:19:55Z","timestamp":1741180795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An effective MRI perfusion threshold based workflow to triage additional 18F-FET PET in posttreatment high grade glioma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7078-2599","authenticated-orcid":false,"given":"Krishna Ranjith","family":"Kadali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0992-6867","authenticated-orcid":false,"given":"Nathalie","family":"Nierobisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0899-0466","authenticated-orcid":false,"given":"Fabienne","family":"Maibach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5090-4935","authenticated-orcid":false,"given":"Philip","family":"Heesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6146-7972","authenticated-orcid":false,"given":"Paula","family":"Alcaide-Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4849-3292","authenticated-orcid":false,"given":"Martin","family":"H\u00fcllner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6805-5150","authenticated-orcid":false,"given":"Zsolt","family":"Kulcsar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0916-7387","authenticated-orcid":false,"given":"Nicolin","family":"Hainc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"90472_CR1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6685","author":"N Soni","year":"2020","unstructured":"Soni, N., Ora, M., Mohindra, N., Menda, Y. & Bathla, G. Diagnostic performance of PET and perfusion-weighted imaging in differentiating tumor recurrence or progression from radiation necrosis in posttreatment gliomas: A review of literature. Am. J. Neuroradiol. https:\/\/doi.org\/10.3174\/ajnr.A6685 (2020). ajnr;ajnr.A6685v1.","journal-title":"Am. J. Neuroradiol."},{"key":"90472_CR2","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller, M. et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 18, e315\u2013e329. https:\/\/doi.org\/10.1016\/S1470-2045(17)30194-8 (2017).","journal-title":"Lancet Oncol."},{"key":"90472_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/biomedicines10020285","volume":"10","author":"I Sidibe","year":"2022","unstructured":"Sidibe, I., Tensaouti, F., Roques, M., Cohen-Jonathan-Moyal, E. & Laprie, A. Pseudoprogression in glioblastoma: Role of metabolic and functional MRI-systematic review. Biomedicines 10, 285. https:\/\/doi.org\/10.3390\/biomedicines10020285 (2022).","journal-title":"Biomedicines"},{"key":"90472_CR4","doi-asserted-by":"publisher","first-page":"111076","DOI":"10.1016\/j.ejrad.2023.111076","volume":"167","author":"N Nierobisch","year":"2023","unstructured":"Nierobisch, N. et al. Comparison of clinically available dynamic susceptibility contrast post processing software to differentiate progression from pseudoprogression in post-treatment high grade glioma. Eur. J. Radiol. 167, 111076. https:\/\/doi.org\/10.1016\/j.ejrad.2023.111076 (2023).","journal-title":"Eur. J. Radiol."},{"key":"90472_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s11864-011-0157-1","volume":"12","author":"J Fink","year":"2011","unstructured":"Fink, J., Born, D. & Chamberlain, M. C. Pseudoprogression: Relevance with respect to treatment of high-grade gliomas. Curr. Treat. Options Oncol. 12, 240\u2013252. https:\/\/doi.org\/10.1007\/s11864-011-0157-1 (2011).","journal-title":"Curr. Treat. Options Oncol."},{"key":"90472_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s40478-023-01587-w","volume":"11","author":"W Wang","year":"2023","unstructured":"Wang, W. et al. Glioblastoma pseudoprogression and true progression reveal spatially variable transcriptional differences. Acta Neuropathol. Commun. 11, 192. https:\/\/doi.org\/10.1186\/s40478-023-01587-w (2023).","journal-title":"Acta Neuropathol. Commun."},{"key":"90472_CR7","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3171\/2022.12.JNS222173","volume":"139","author":"JS Young","year":"2023","unstructured":"Young, J. S., Al-Adli, N., Scotford, K., Cha, S. & Berger, M. S. Pseudoprogression versus true progression in glioblastoma: What neurosurgeons need to know. J. Neurosurg. 139, 748\u2013759. https:\/\/doi.org\/10.3171\/2022.12.JNS222173 (2023).","journal-title":"J. Neurosurg."},{"key":"90472_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nic.2020.09.010","volume":"31","author":"SB Strauss","year":"2021","unstructured":"Strauss, S. B., Meng, A., Ebani, E. J. & Chiang, G. C. Imaging glioblastoma posttreatment. Neuroimaging Clin. 31, 103\u2013120. https:\/\/doi.org\/10.1016\/j.nic.2020.09.010 (2021).","journal-title":"Neuroimaging Clin."},{"key":"90472_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot, O. L. et al. Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345 (2014).","journal-title":"N. Engl. J. Med."},{"key":"90472_CR10","doi-asserted-by":"publisher","first-page":"e071327","DOI":"10.1136\/bmjopen-2022-071327","volume":"13","author":"E-S Koh","year":"2023","unstructured":"Koh, E-S. et al. [18 F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: Protocol for a prospective, multicentre PET\/CT trial. BMJ Open 13, e071327. https:\/\/doi.org\/10.1136\/bmjopen-2022-071327 (2023).","journal-title":"BMJ Open"},{"key":"90472_CR11","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2967\/jnumed.122.265149","volume":"64","author":"NJ Smith","year":"2023","unstructured":"Smith, N. J. et al. Hybrid 18 F-fluoroethyltyrosine PET and MRI with perfusion to Distinguish disease progression from treatment-related change in malignant brain tumors: The quest to beat the toughest cases. J. Nucl. Med. 64, 1087\u20131092. https:\/\/doi.org\/10.2967\/jnumed.122.265149 (2023).","journal-title":"J. Nucl. Med."},{"key":"90472_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/neuonc\/noae049","volume":"26","author":"N Galldiks","year":"2024","unstructured":"Galldiks, N. et al. Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET\/RANO group. Neuro Oncol. 26, 1181\u20131194. https:\/\/doi.org\/10.1093\/neuonc\/noae049 (2024).","journal-title":"Neuro Oncol."},{"key":"90472_CR13","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.3390\/cancers14143336","volume":"14","author":"A Heinzel","year":"2022","unstructured":"Heinzel, A. et al. Two decades of brain tumour imaging with O-(2-[18F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum J\u00fclich experience. Cancers 14, 3336. https:\/\/doi.org\/10.3390\/cancers14143336 (2022).","journal-title":"Cancers"},{"key":"90472_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00259-014-2959-4","volume":"42","author":"N Galldiks","year":"2015","unstructured":"Galldiks, N. et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur. J. Nucl. Med. Mol. Imaging 42, 685\u2013695. https:\/\/doi.org\/10.1007\/s00259-014-2959-4 (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"90472_CR15","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/neuonc\/nov088","volume":"17","author":"N Galldiks","year":"2015","unstructured":"Galldiks, N. et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-Oncol 17, 1293\u20131300. https:\/\/doi.org\/10.1093\/neuonc\/nov088 (2015).","journal-title":"Neuro-Oncol"},{"key":"90472_CR16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131, 803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1 (2016).","journal-title":"Acta Neuropathol."},{"key":"90472_CR17","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 23, 1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106 (2021).","journal-title":"Neuro Oncol."},{"key":"90472_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3174\/ajnr.A6358","volume":"41","author":"DJ Leao","year":"2020","unstructured":"Leao, D. J., Craig, P. G., Godoy, L. F., Leite, C. C. & Policeni, B. Response assessment in neuro-oncology criteria for gliomas: Practical approach using conventional and advanced techniques. AJNR Am. J. Neuroradiol. 41, 10\u201320. https:\/\/doi.org\/10.3174\/ajnr.A6358 (2020).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"90472_CR19","first-page":"859","volume":"27","author":"JL Boxerman","year":"2006","unstructured":"Boxerman, J. L., Schmainda, K. M. & Weisskoff, R. M. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am. J. Neuroradiol. 27, 859\u2013867 (2006).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"90472_CR20","doi-asserted-by":"publisher","first-page":"E79","DOI":"10.3174\/ajnr.A5276","volume":"38","author":"S Haller","year":"2017","unstructured":"Haller, S. The Concept of Number needed to image. AJNR Am. J. Neuroradiol. 38, E79\u201380. https:\/\/doi.org\/10.3174\/ajnr.A5276 (2017).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"90472_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/neuonc\/now148","volume":"19","author":"P Patel","year":"2017","unstructured":"Patel, P. et al. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: A systematic review and meta-analysis. Neuro Oncol. 19, 118\u2013127. https:\/\/doi.org\/10.1093\/neuonc\/now148 (2017).","journal-title":"Neuro Oncol."},{"key":"90472_CR22","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.3390\/cancers15143577","volume":"15","author":"K-J Langen","year":"2023","unstructured":"Langen, K-J. et al. Hybrid PET\/MRI in cerebral glioma: Current status and perspectives. Cancers 15, 3577. https:\/\/doi.org\/10.3390\/cancers15143577 (2023).","journal-title":"Cancers"},{"key":"90472_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/cancers15010083","volume":"15","author":"J Ziegenfeuter","year":"2023","unstructured":"Ziegenfeuter, J. et al. Sequential and hybrid PET\/MRI acquisition in follow-up examination of glioblastoma show similar diagnostic performance. Cancers 15, 83. https:\/\/doi.org\/10.3390\/cancers15010083 (2023).","journal-title":"Cancers"},{"key":"90472_CR24","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1007\/s00259-020-05114-0","volume":"48","author":"E Steidl","year":"2021","unstructured":"Steidl, E. et al. Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes. Eur. J. Nucl. Med. Mol. Imaging 48, 1956\u20131965. https:\/\/doi.org\/10.1007\/s00259-020-05114-0 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"90472_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2967\/jnumed.119.234757","volume":"61","author":"GD Maurer","year":"2020","unstructured":"Maurer, G. D. et al. 18F-FET PET imaging in differentiating glioma progression from treatment-related changes: A single-center experience. J. Nucl. Med. 61, 505\u2013511. https:\/\/doi.org\/10.2967\/jnumed.119.234757 (2020).","journal-title":"J. Nucl. Med."},{"key":"90472_CR26","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1097\/RLU.0000000000003879","volume":"47","author":"N Lohaus","year":"2022","unstructured":"Lohaus, N., Mader, C., Jelcic, I., Reimann, R. & Huellner, M. W. Acute disseminated encephalomyelitis in FET PET\/MR. Clin. Nucl. Med. 47, e137\u2013e139. https:\/\/doi.org\/10.1097\/RLU.0000000000003879 (2022).","journal-title":"Clin. Nucl. Med."},{"key":"90472_CR27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.248278","author":"N Galldiks","year":"2020","unstructured":"Galldiks, N. et al. Treatment monitoring of Immunotherapy and targeted therapy using 18F-FET PET in patients with melanoma and lung cancer brain metastases: Initial experiences. J. Nucl. Med. https:\/\/doi.org\/10.2967\/jnumed.120.248278 (2020).","journal-title":"J. Nucl. Med."},{"key":"90472_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2967\/jnumed.112.109603","volume":"54","author":"M Rapp","year":"2013","unstructured":"Rapp, M. et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J. Nucl. Med. 54, 229\u2013235. https:\/\/doi.org\/10.2967\/jnumed.112.109603 (2013).","journal-title":"J. Nucl. Med."},{"key":"90472_CR29","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/neuonc\/now058","volume":"18","author":"NL Albert","year":"2016","unstructured":"Albert, N. L. et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 18, 1199\u20131208. https:\/\/doi.org\/10.1093\/neuonc\/now058 (2016).","journal-title":"Neuro Oncol."},{"key":"90472_CR30","unstructured":"Bheda, K. TLX101-CDx (Pixclara\u2122) Granted FDA Fast Track Designation. Telix Pharm. https:\/\/telixpharma.com\/news-views\/tlx101-cdx-pixclara-granted-fda-fast-track-designation\/. Accessed 21 Oct 2024 (2024)."},{"key":"90472_CR31","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00259-012-2093-0","volume":"39","author":"A Heinzel","year":"2012","unstructured":"Heinzel, A., Stock, S., Langen, K-J. & M\u00fcller, D. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur. J. Nucl. Med. Mol. Imaging 39, 1089\u20131096. https:\/\/doi.org\/10.1007\/s00259-012-2093-0 (2012).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"90472_CR32","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2967\/jnumed.113.120089","volume":"54","author":"A Heinzel","year":"2013","unstructured":"Heinzel, A. et al. The use of O-(2-18F-fluoroethyl)-l-tyrosine PET for treatment management of Bevacizumab and Irinotecan in patients with recurrent high-grade glioma: A cost-effectiveness analysis. J. Nucl. Med. 54, 1217\u20131222. https:\/\/doi.org\/10.2967\/jnumed.113.120089 (2013).","journal-title":"J. Nucl. Med."},{"key":"90472_CR33","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3389\/fonc.2019.01134","volume":"9","author":"A Moreau","year":"2019","unstructured":"Moreau, A., Febvey, O., Mognetti, T., Frappaz, D. & Kryza, D. Contribution of different positron emission tomography tracers in glioma management: Focus on glioblastoma. Front. Oncol. 9, 1134. https:\/\/doi.org\/10.3389\/fonc.2019.01134 (2019).","journal-title":"Front. Oncol."},{"key":"90472_CR34","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/jon.12914","volume":"31","author":"AD Puranik","year":"2021","unstructured":"Puranik, A. D. et al. Brain FET PET tumor-to-white mater ratio to differentiate recurrence from post-treatment changes in high-grade gliomas. J. Neuroimaging 31, 1211\u20131218. https:\/\/doi.org\/10.1111\/jon.12914 (2021).","journal-title":"J. Neuroimaging"},{"key":"90472_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jocn.2018.09.009","volume":"58","author":"DL Chan","year":"2018","unstructured":"Chan, D. L. et al. FET PET in the evaluation of indeterminate brain lesions on MRI: Differentiating glioma from other non-neoplastic causes\u2014a pilot study J. Clin. Neurosci. 58, 130\u2013135. https:\/\/doi.org\/10.1016\/j.jocn.2018.09.009 (2018).","journal-title":"J. Clin. Neurosci."},{"key":"90472_CR36","doi-asserted-by":"publisher","first-page":"743655","DOI":"10.3389\/fonc.2021.743655","volume":"11","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Glioma imaging by O-(2-18F-fluoroethyl)-L-tyrosine PET and diffusion-weighted MRI and correlation with molecular phenotypes, validated by PET\/MR-guided biopsies. Front. Oncol. 11, 743655. https:\/\/doi.org\/10.3389\/fonc.2021.743655 (2021).","journal-title":"Front. Oncol."},{"key":"90472_CR37","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1007\/s00259-019-04656-2","volume":"47","author":"S Song","year":"2020","unstructured":"Song, S. et al. Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET\/MR improves delineation of tumor spatial biodistribution in gliomas: A biopsy validation study. Eur. J. Nucl. Med. Mol. Imaging 47, 1458\u20131467. https:\/\/doi.org\/10.1007\/s00259-019-04656-2 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"90472_CR38","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.1097\/RLU.0000000000004201","volume":"47","author":"SY Kang","year":"2022","unstructured":"Kang, S. Y., Moon, B. S., Yoo, M. Y., Yoon, H-J. & Kim, B. S. Clinical usefulness of 18 F-FET PET in a pediatric patient with suspected demyelinating disease. Clin. Nucl. Med. 47, e562\u2013e564. https:\/\/doi.org\/10.1097\/RLU.0000000000004201 (2022).","journal-title":"Clin. Nucl. Med."},{"key":"90472_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/1874471012666190111111046","volume":"12","author":"C Stegmayr","year":"2019","unstructured":"Stegmayr, C., Willuweit, A., Lohmann, P. & Langen, K-J. O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) in neurooncology: A review of experimental results. Curr. Radiopharm. 12, 201\u2013210. https:\/\/doi.org\/10.2174\/1874471012666190111111046 (2019).","journal-title":"Curr. Radiopharm"},{"key":"90472_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ymeth.2017.05.019","volume":"130","author":"K-J Langen","year":"2017","unstructured":"Langen, K-J. et al. Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine (FET). Methods  130, 124\u2013134. https:\/\/doi.org\/10.1016\/j.ymeth.2017.05.019 (2017).","journal-title":"Methods"},{"key":"90472_CR41","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/neuonc\/noaa141","volume":"22","author":"JL Boxerman","year":"2020","unstructured":"Boxerman, J. L. et al. Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro Oncol. 22, 1262\u20131275. https:\/\/doi.org\/10.1093\/neuonc\/noaa141 (2020).","journal-title":"Neuro Oncol."},{"key":"90472_CR42","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","volume":"25","author":"NL Albert","year":"2024","unstructured":"Albert, N. L. et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): A report of the RANO group. Lancet Oncol. 25, e29\u2013e41. https:\/\/doi.org\/10.1016\/S1470-2045(23)00525-9 (2024).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90472-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90472-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90472-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:45:33Z","timestamp":1741221933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90472-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90472"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90472-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"7 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: MH is a recipient of grants by GE Healthcare, the Alfred and Annemarie von Sick legacy and the Clinical Research Priority Program (CRPP) Artificial Intelligence in Oncological Imaging Network (University of Zurich). None of the other authors has any conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7749"}}